This Article Full Text Full Text (PDF) IMPORTANT FDA ADVISORY eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lipton, A. Search for Related Content PubMed PubMed Citation Articles by Lipton, A.

Toward New Horizons: The Future of Bisphosphonate Therapy

Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

Correspondence: Allan Lipton, M.D., Penn State University, College of Medicine, Milton S. Hershey Medical Center, 500 University Drive, Hershey, Pennsylvania 17033, USA. Telephone: 717-531-5960; Fax: 717-531-5076; e-mail: alipton{at}psu.edu

Bisphosphonate therapy has become a standard of care for patients with malignant bone disease. In addition, preclinical and preliminary clinical data suggest that bisphosphonates may prevent cancer-treatment-induced bone loss (CTIBL) and the development of malignant bone disease in patients with early-stage cancer. Patients who receive adjuvant hormonal therapy for breast cancer or androgen-deprivation therapy for prostate cancer are at an especially high risk for CTIBL because of reduced estrogenic signaling. Oral clodronate (Bonefos^®; Anthra Pharmaceuticals; Princeton, NJ), oral risedronate (Actonel^®; Proctor and Gamble Pharmaceuticals, Inc.; Cincinnati, OH), and i.v. zoledronic acid (Zometa^®; Novartis Pharmaceuticals Corp.; East Hanover, NJ) have all demonstrated promise in preventing CTIBL in patients receiving hormonal therapy for breast cancer. Zoledronic acid has demonstrated efficacy with the longest between-treatment interval (3–6 months) and is currently being investigated in the Zometa^®/Femara^® Adjuvant Synergy Trials (Z-FAST and ZO-FAST in the United States and Europe, respectively). In patients receiving androgen-deprivation therapy for prostate cancer, i.v. pamidronate (Aredia^®; Novartis Pharmaceuticals Corp.) and i.v. zoledronic acid both have demonstrated significant benefits over placebo, but only zoledronic acid produced significant increases in bone mineral density compared with baseline values. Additionally, bisphosphonates have demonstrated antitumor activities in preclinical models, and clinical trials with oral clodronate suggest that bisphosphonates might prevent or delay bone metastasis in patients with early-stage breast cancer. Clinical trials are investigating the effect of zoledronic acid on disease progression in patients with breast cancer, prostate cancer, and non-small cell lung cancer. The results of these clinical trials should further define the clinical benefit of bisphosphonates in the oncology setting.

Key Words. Adjuvant therapy • Bisphosphonates • Cancer-treatment-induced bone loss • Clodronate • Prostate cancer • Zoledronic acid

This article has been cited by other articles:

				A. M. Brufsky Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives Oncologist, February 1, 2008; 13(2): 187 - 195. [Abstract] [Full Text] [PDF]

				K. Mystakidou, E. Katsouda, E. Parpa, E. Kouskouni, C. Chondros, M. L. Tsiatas, A. Galanos, and L. Vlahos A prospective randomized controlled clinical trial of zoledronic acid for bone metastases American Journal of Hospice and Palliative Medicine, January 1, 2006; 23(1): 41 - 50. [Abstract] [PDF]

				P. Conte Optimizing Bisphosphonate Therapy in Oncology Oncologist, September 1, 2004; 9(suppl_4): 1 - 2. [Full Text] [PDF]